Diagnosis of rupture of membranes: AmniSure, clinical assessment, and the Food and Drug Administration warning.

Thumm, Brie; Walsh, Geri; Heyborne, Kent D

Thumm, Brie; Walsh, Geri; Heyborne, Kent D.

Afiliação

Thumm B; Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO. Electronic address: brie.thumm@dhha.org.
Walsh G; Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO.
Heyborne KD; Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, CO; Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO.

Am J Obstet Gynecol MFM ; 2(4): 100200, 2020 11.

Article em En | MEDLINE | ID: mdl-33345917

Assuntos

Ruptura Prematura de Membranas Fetais; Serviços de Saúde Materna; Feminino; Ruptura Prematura de Membranas Fetais/diagnóstico; Humanos; Recém-Nascido; Placenta; Gravidez; Estudos Retrospectivos; Estados Unidos; United States Food and Drug Administration

Palavras-chave

AmniSure; placental alpha microglobulin-1; premature rupture of membranes; rupture of membranes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ruptura Prematura de Membranas Fetais / Serviços de Saúde Materna Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google